SynBioBeta Speaker
Stuart Sevier
IMI
President
Stuart Sevier is a media and technology leader building ecosystems of trust in science and public information. He is the Founder and CEO of ATOM Technologies, where he leads the development of cryptographic and provenance-based systems that capture reality at the source—helping establish what is real in images and video amid AI-generated and synthetic content.Stuart is also the President and Co-Founder of the Independent Media Initiative (IMI), a nonprofit reimagining public media for the 21st century. IMI pairs independent creators with working scientists to produce credible, large-scale public-interest media—often described as PBS meets Sundance for YouTube—amplifying science and research to broad, diverse audiences.Before founding ATOM and IMI, he was a research fellow in systems biology at Harvard Medical School and in physics at Massachusetts Institute of Technology. His work explored the mechanical properties of DNA and how physical structure encodes biological information, shaping processes such as transcription, replication, and cellular memory.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Stuart
This Year
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Inst Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Sr Dir, Strat & Ops
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Inst Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Sr Dir, Strat & Ops
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
